Gilead and Galapagos’ filgotinib succeeds in ankylosing spondylitis trial

Image: Gilead Sciences and Galapagos’ filgotinib has achieved its primary efficacy endpoint in active ankylosing spondylitis study. Photo: courtesy of stockdevil / FreeDigitalPhotos.net.